Development of lipidomic platform and phosphatidylcholine retention time index for lipid profiling of rosuvastatin treated human plasma

Biochemistry, Genetics and Molecular Biology

• Biomembrane 12%
• Blood Level 12%
• Chloroform 25%
• Drug Response 25%
• Lipidomics 100%
• Liquid Liquid Extraction 12%
• Lysophosphatidic Acid 12%
• Lysophosphatidylcholine 25%
• Mobile Phase Composition 25%
• Phosphatidylcholine 100%
• Phosphatidylethanolamine 25%
• Phosphatidylglycerol 12%
• Phosphatidylinositol 25%
• Phosphatidylserine 12%
• Retention Time 100%
• Rosuvastatin 100%
• Sphingomyelin 25%
• Time-of-Flight Mass Spectrometry 12%
• Ultra High Performance Liquid Chromatography 12%

Chemistry

• Acetonitrile 25%
• Ammonium Acetate 25%
• Antilipemic Agent 12%
• Chloroform 25%
• Lysophosphatidic Acid 12%
• Lysophosphatidylcholine 25%
• Methanol 25%
• Mobile Phase Composition 25%
• Phosphatidylcholine 100%
• Phosphatidylethanolamine 25%
• Phosphatidylglycerol 12%
• Phosphatidylinositol 25%
• Phosphatidylserine 12%
• Plasma Level 12%
• Quadrupole Time-of-Flight Mass Spectrometry 12%
• Retention Time 100%
• Rosuvastatin 100%
• Salting Out 12%
• Sodium Chloride 12%
• Solvent Extraction 12%
• Sphingomyelin 25%
• Triacylglycerol 25%
• Ultra Performance Liquid Chromatography 12%

Medicine and Dentistry

• 2 Propanol 14%
• Acetonitrile 28%
• Ammonium Acetate 28%
• Biomembrane 14%
• Chloroform 28%
• Drug Response 28%
• Hypolipidemic Agent 14%
• Lipidomics 100%
• Lysophosphatidic Acid 14%
• Lysophosphatidylcholine 28%
• Methanol 28%
• Mobile Phase Composition 28%
• Phosphatidylethanolamine 28%
• Phosphatidylglycerol 14%
• Phosphatidylinositol 28%
• Phosphatidylserine 14%
• Rosuvastatin 100%
• Side Effect 14%
• Sphingomyelin 28%
• Time-of-Flight Mass Spectrometry 14%
• Ultra Performance Liquid Chromatography 14%